Results 1 to 10 of about 14,455 (195)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]

Drugs in R&D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell, Benjamin C. Kennard, Maria E. Bertoni, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Kesheng Wang, Michelle M. Duffourc, Sam Harirforoosh   +8 more
doaj   +6 more sources

Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B [PDF]

Frontiers in Medicine, 2022
BackgroundTenofovir alafenamide fumarate has been used in late pregnancy; however, no data exist regarding its safety and effectiveness in early and middle pregnancy for mothers with hepatitis B virus infection.AimsTo design a prospective study to ...
Ruochan Chen, Ruochan Chen, Ju Zou, Ju Zou, Liyuan Long, Liyuan Long, Haiyue Huang, Min Zhang, Min Zhang, Xuegong Fan, Xuegong Fan, Yan Huang, Yan Huang, Yan Huang   +13 more
doaj   +3 more sources

Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis [PDF]

Brazilian Journal of Nephrology
Introduction: Tenofovir disoproxil fumarate (TDF) is effective in treating hepatitis B virus, (HBV) but has been associated with nephrotoxicity. In contrast, tenofovir alafenamide fumarate (TAF) has emerged as a safer alternative, reducing kidney ...
João Galdino de Pascoa Junior, Ramon Huntermann, Victor Machado Viana Gomes, Frederico de Sousa Marinho Mendes Filho, João Marcelo Vallim Bertozzi, Paulo Ricardo Gessolo Lins   +5 more
doaj   +3 more sources

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. [PDF]

Clin Infect Dis, 2023
BACKGROUND: We evaluated the pharmacokinetics of tenofovir alafenamide fumarate (TAF) and tenofovir in a subset of African children enrolled in the CHAPAS-4 trial.
Waalewijn H, Szubert AJ, Wasmann RE, Wiesner L, Chabala C, Bwakura-Dangarembizi M, Makumbi S, Nangiya J, Mumbiro V, Mulenga V, Musiime V, Monkiewicz LN, Griffiths AL, Bamford A, Doerholt K, Denti P, Burger DM, Gibb DM, McIlleron HM, Colbers A, Children with HIV in Africa – Pharmacokinetics and Acceptability of Simple second-line antiretroviral regimens (CHAPAS-4) Trial Team.   +20 more
europepmc   +4 more sources

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Continued use of tenofovir disoproxil fumarate (TDF), an antiretroviral drug, causes renal function decline and tubular damage in individuals with HIV. While tenofovir alafenamide fumarate (TAF) may have less damaging effects, it causes weight
Kensuke Abe, Junji Imamura, Akiko Sasaki, Tomoko Suzuki, Satomi Kamio, Taku Obara, Toshihiro Ito   +6 more
doaj   +3 more sources

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients [PDF]

Infection and Drug Resistance, 2023
Jingjing He, Yifei Guo, Yao Zhang, Jiajia Han, Jingwen Chen, Yidi Jia, Zhenxuan Ma, Jingwen Wu, Shenyan Zhang, Fahong Li, Richeng Mao, Jiming Zhang Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency ...
He J, Guo Y, Zhang Y, Han J, Chen J, Jia Y, Ma Z, Wu J, Zhang S, Li F, Mao R, Zhang J   +11 more
doaj   +3 more sources

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide [PDF]

Drugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi, Mikayla Johnson, Thomas D Chiampas, Eric Wenzler, Rodrigo M Burgos, Renata O Smith, Melissa E Badowski   +6 more
doaj   +3 more sources

Optimized strategy of switching to tenofovir alafenamide fumarate treatment for nucleos(t)ide analogue experienced patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Background This study aimed to evaluate the efficacy and safety of tenofovir alafenamide fumarate (TAF) in nucleos(t)ide analogue (NA)-experienced patients with chronic hepatitis B (CHB) who exhibited partial virological response (PRT) or low-level ...
Hu X, Kong Y, Liu Y, Liu T, Ma A, Li Y, Zhang Y, Li J, Zhang L, Li G.   +9 more
europepmc   +2 more sources

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide [PDF]

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +3 more sources

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. [PDF]

Sci Rep
Daily oral pre-exposure prophylaxis (PrEP), including emtricitabine/tenofovir disoproxil fumarate (TDF) and emtricitabine/tenofovir alafenamide fumarate (TAF), is a key strategy for HIV prevention.
Shi F, Xia H, Weissman S, Li X, Yang X.
europepmc   +2 more sources